Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment

Next Previous
Trial Profile

A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Certolizumab pegol (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary) ; Triamcinolone (Primary) ; Azathioprine; Corticosteroids; Glucocorticoids; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Prednisolone; Prednisone; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms NORD-STAR

Most Recent Events

  • 15 Jun 2024 Results (n=239) of an analysis assessing Ultrasound remission rates after 1 year in early RA patients on induction treatment in a subset of patients in Norway and Sweden presented at the 25th Annual Congress of the European League Against Rheumatism
  • 15 Jun 2024 Results (n=220 adults with untreated newly diagnosed RA, randomly selected from the Swedish arm of the NORD-STAR study cohort) to identify serum metabolites associated with disease activity and therapeutic response in a large cohort of people with untreated early RA, presented at the 25th Annual Congress of the European League Against Rheumatism.
  • 15 Jun 2024 Results(n=812) presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top